Remicade (infliximab) denied as duplicate or overlapping therapy by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UnitedHealthcare May Deny Remicade (Infliximab) as Duplicate Therapy

UnitedHealthcare's utilization-management systems may flag Remicade (infliximab) as "duplicate therapy" when the patient's active medication profile already includes another biologic or targeted immunomodulator — most commonly another TNF inhibitor or a biologic from a different mechanism class — that UHC considers to be addressing the same clinical indication. This is an automated flag, not a clinical determination that combination use is wrong; it reflects UHC's standard policy against concurrent coverage of agents it deems to overlap.

## Why This Denial Is Appealable

Duplicate-therapy denials are appealable when the prescriber has a documented clinical rationale for the combination: for example, that the two agents are targeting distinct disease components, that a transition is in progress and overlap is intentional and time-limited, or that prior monotherapy with each agent individually was inadequate. Documented clinical reasoning from the treating specialist routinely overrides an automated duplicate-therapy flag.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 and ACA §2719, you have the right to a full-and-fair internal review. UHC must provide the specific clinical criteria used and why they were not met.
• External review: After a final internal denial, escalate to an independent external review within approximately four months. The reviewer applies objective clinical standards, not UHC's internal policy alone.
• Expedited review: If withholding Remicade would seriously jeopardize health or ability to regain maximum function, request expedited review simultaneously.

## Documentation to Gather

1. Prescriber explanation of the treatment plan — a detailed letter from the treating gastroenterologist, rheumatologist, or relevant specialist explaining why both agents are being used, what each is targeting, and why this combination is medically necessary for this patient's specific disease pattern. 2. Treatment history — dated records of each prior agent tried as monotherapy, response achieved, and reason the current combination or transition plan was selected. 3. Current disease-activity documentation — recent clinical notes, objective disease-activity assessments referenced by date, and any relevant lab or imaging findings documented in the chart. 4. UHC's current duplicate-therapy policy — obtain from UHC's provider portal to understand exactly which agent UHC considers duplicative and what exceptions, if any, are enumerated.

## Criteria-Mapping Structure

| UHC Duplicate-Therapy Criterion (copy verbatim) | Patient-Specific Clinical Response | |---|---| | Definition of "duplicate" as stated in policy | Why the two agents are clinically distinct in this patient | | Any exception criteria listed in policy | Corresponding chart documentation | | Active concurrent medications | Prescriber rationale for each |

A specialist attestation addressing each policy criterion directly is the cornerstone of a successful duplicate-therapy appeal.